Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase II neoadjuvant study

Journal of Clinical Oncology

Volumn 32, Issue 33, 2014, Pages 3705-3715

  Taplin, Mary Ellen ^a   Montgomery, Bruce ^d   Logothetis, Christopher J ^g   Bubley, Glenn J ^b   Richie, Jerome P ^c   Dalkin, Bruce L ^d   Sanda, Martin G ^h   Davis, John W ^g   Loda, Massimo ^a,c,i   True, Lawrence D ^d   Troncoso, Patricia ^g   Ye, Huihui ^b   Lis, Rosina T ^a,c   Marck, Brett T ^e   Matsumoto, Alvin M ^d,e   Balk, Steven P ^b   Mostaghel, Elahe A ^f   Penning, Trevor M ^j   Nelson, Peter S ^f   Xie, Wanling ^a   Jiang, Zhenyang ^a   Haqq, Christopher M ^k   Tamae, Daniel ^j   Tran, NamPhuong ^k   Peng, Weimin ^k   Kheoh, Thian ^k   Molina, Arturo ^k   Kantoff, Philip W ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ALANINE AMINOTRANSFERASE; ANDROSTANOLONE; ASPARTATE AMINOTRANSFERASE; LEUPRORELIN; PRASTERONE; PRASTERONE SULFATE; PREDNISONE; PREGNENOLONE; PROGESTERONE; TESTOSTERONE; ANDROGEN RECEPTOR; ANDROSTANE DERIVATIVE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURGERY; CHEMOTHERAPY INDUCED ANEMIA; CONTROLLED STUDY; DEPRESSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GLEASON SCORE; HEADACHE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INSOMNIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS;

ABIRATERONE ACETATE; AGED; ANDROGEN ANTAGONISTS; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE;

EID: 84905993578     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.4578     Document Type: Article

References (30)

1. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
2. Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101, 2005
3. Albertsen PC: The face of high risk prostate cancer. World J Urol 26:205-210, 2008
4. Aus G, Abrahamsson PA, Ahlgren G, et al: Hormonal treatment before radical prostatectomy: A 3-year followup. J Urol 159:2013-2016, 1998
5. Fair WR, Cookson MS, Stroumbakis N, et al: The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 49:46-55, 1997
6. Klotz LH, Goldenberg SL, Jewett M, et al: CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results - Canadian Urologic Oncology Group. Urology 53:757-763, 1999
7. Meyer F, Moore L, Bairati I, et al: Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol 162: 2024-2028, 1999
8. Soloway MS, Pareek K, Sharifi R, et al: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167:112-116, 2002
9. Gleave ME, Goldenberg SL, Chin JL, et al: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects. J Urol 166:500-506, 2001
10. Mostaghel EA, Nelson PS, Lange P, et al: Targeted androgen pathway suppression in localized prostate cancer: A pilot study. J Clin Oncol 32:229-237, 2014
11. Mostaghel EA, Page ST, Lin DW, et al: Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033-5041, 2007
12. O'Donnell A, Judson I, Dowsett M, et al: Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90:2317-2325, 2004
13. Attard G, Reid AH, Yap TA, et al: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563-4571, 2008
14. Bonkhoff H, Berges R: From pathogenesis to prevention of castration resistant prostate cancer. Prostate 70:100-112, 2010
15. Montgomery RB, Mostaghel EA, Vessella R, et al: Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68:4447-4454, 2008
16. Scher HI, Sawyers CL: Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253-8261, 2005
17. Van Allen EM, Ryan CJ: Novel secondary hormonal therapy in advanced prostate cancer: An update. Curr Opin Urol 19:315-321, 2009
18. Chen ME, Johnston D, Reyes AO, et al: A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 27:1291-1301, 2003
19. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
20. Fizazi K, Scher HI, Molina A, et al: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983-992, 2012
21. Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013
22. Page ST, Lin DW, Mostaghel EA, et al: Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: A randomized-controlled trial. J Clin Endocrinol Metab 96:430-437, 2011
23. Wright JL, Kwon EM, Ostrander EA, et al: Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev 20:619-627, 2011
24. Yang M, Xie W, Mostaghel E, et al: SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 29:2565-2573, 2011
25. Reference deleted
26. Febbo PG, Richie JP, George DJ, et al: Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11:5233-5240, 2005
27. Ross RW, Galsky MD, Febbo P, et al: Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Cancer 118:4777-4784, 2012
28. Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32, 2012
29. Taplin M-E, Montgomery RB, Logothetis C, et al: Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. J Clin Oncol 30:282s, 2012 (suppl; abstr 4521)
30. Attard G, Reid AH, Auchus RJ, et al: Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 97:507-516, 2012